Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Mark D, Talley J, Topol E, Bowman L, Lam L, Anderson K, Jollis J, Cleman M, Lee K, Aversano T, Untereker W, Davidson-Ray L, Califf R. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996, 94: 629-35. PMID: 8772681, DOI: 10.1161/01.cir.94.4.629.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplastyAntibodies, MonoclonalAnticoagulantsAspirinBlood TransfusionCosts and Cost AnalysisDouble-Blind MethodFemaleHeparinHumansImmunoglobulin Fab FragmentsInfusions, IntravenousInjections, IntravenousMaleMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecurrenceStentsTreatment OutcomeUnited StatesConceptsHigh-risk coronary angioplastyC7E3 FabIschemic eventsCoronary angioplastyInitial hospitalizationPlatelet glycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionAggressive platelet inhibitionBaseline medical costsIschemic end pointsReduced ischemic eventsAcute ischemic eventsCost of therapyEPIC trialMajor bleedingBleeding episodesIschemic complicationsStandard carePlatelet inhibitionHospitalization ratesReceptor antibodiesHospital costsMedical costsMedicare fee
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply